BioCryst Pharmaceuticals has been granted a patent for compounds inhibiting the complement system, useful in treating diseases with complement system abnormalities. The patent covers methods of treatment and pharmaceutical compositions containing these compounds. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11866418B2) discloses a method for treating diseases or conditions characterized by aberrant complement system activity. The method involves administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt selected from a specific group of compounds. The diseases or conditions targeted by this method include paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, and catastrophic antiphospholipid syndrome.
Furthermore, the patent specifies that the compound used in the method can be in the form of a hydrochloride salt. This particular form of the compound is highlighted in various claims within the patent, emphasizing its importance in treating diseases or conditions associated with aberrant complement system activity. The method outlined in the patent aims to provide a targeted and effective approach to managing these specific medical conditions by utilizing the identified compounds or their hydrochloride salt forms.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
